Arcus Biosciences Inc (NYSE:RCUS) Share Price

Company Profile

Business description
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Contact
3928 Point Eden Way
HaywardCA94545
USA
T: +1 510 694-6200
E: [email protected]
https://www.arcusbio.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
674

Recommended

As investors toil in complexity the obvious solution may be the right one.

Mark LaMonica, CFA | 24 July 2025

Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.

Matthew Dolgin, CFA | 23 July 2025

A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.

John Abernethy | 23 July 2025

Index	Last price	Change	% Change
All Ordinaries	8,934.30	45.10	-0.50%
CAC 40	7,834.58	16.30	0.21%
DAX 40	24,217.50	78.43	-0.32%
Dow JONES (US)	44,749.20	55.29	0.12%
FTSE 100	9,120.31	18.06	-0.20%
HKSE	25,388.35	278.83	-1.09%
NASDAQ	21,118.85	60.89	0.29%
Nikkei 225	41,456.23	370.11	-0.88%
NZX 50 Index	12,853.46	48.33	0.38%
S&P 500	6,379.70	16.35	0.26%
S&P/ASX 200	8,666.90	42.50	-0.49%
SSE Composite Index	3,593.66	12.07	-0.33%